Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 172

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 172
---
 May 2025 Warrants will expire on the five-year anniversary of the later of the Stockholder Approval Notice Date and the effective date of the filing of the Certificate of Amendment. The exercise price and number of shares of Common Stock issuable upon exercise of the May 2025 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price, provided however that, in the event of a reverse stock split, the number of shares underlying the May 2025 Warrants and the exercise price thereof will each be appropriately adjusted according to the reverse stock split ratio. The May 2025 Warrants will be issued separately from the Common Stock and Pre-Funded Warrants and may be transferred separately immediately thereafter. The exercise price is also subject to voluntary adjustment. The May 2025 Warrants will be issued in certificated form only.

The terms of the May 2025 Warrants will also include (i) a one-time thirty percent increase in the number of shares of Common Stock issuable upon exercise of the May 2025 Warrants if a reverse stock split is effected prior to the expiration of the May 2025 Warrants and (ii) subject to Warrant Stockholder Approval, a decrease of the exercise price of the May 2025 Warrants, if in a subsequent offering of our securities the price paid for Common Stock, the exercise price of any options or warrants or the conversion price of any convertible securities issued in such subsequent offering is less than the exercise price immediately prior to such subsequent offering (a “Dilutive Issuance”), to an exercise price that is equal to the lowest of the price paid for Common Stock, the exercise price of any options or warrants or the conversion price of any convertible securities issued in such subsequent offering (subject to a floor of $0.10 per share) and an increase in the number of shares of our Common Stock underlying the May 2025 Warrants so that the reset exercise price multiplied by the increased number of shares equals the aggregate proceeds that would have resulted from the full exercise of the May 2025 Warrants immediately prior to the reset (the “Anti-Dilution Adjustment”). We have agreed not to consummate a subsequent Dilutive Issuance until the earlier of (i) eight months from the closing date of this offering and (ii) later of: (a) the filing of a registration statement registering the resale of the shares issuable as a result of an Anti-D